North America Mosquito Repellent - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The north america mosquito repellent market size is projected to expand from USD 487.9 million in 2025 and USD 510.9 million in 2026 to USD 677.9 million by 2031, registering a CAGR of 5.8% between 2026 and 2031. This report is Segmented by Product Type (Liquid Vaporizer, Creams/Lotions, and More), Ingredient Type (Natural and Conventional), End User (Adults and Kids), Distribution Channel (Supermarkets, Convenience Stores, Pharmacies, Online Retail, and Others), and Geography (United States, Canada, Mexico, and the Rest of North America). Market Forecasts are Provided in Terms of Value (USD).

North America Mosquito Repellent Market Trends and Insights

Rising mosquito-borne disease awareness and preventive spend

In North America, rising cases of vector-borne diseases are driving demand for insect repellents, keeping public health in the spotlight even during lulls between outbreaks. In 2024, the CDC reported 3,798 dengue cases across U.S. states and D.C., marking a staggering 359% surge from the 2010-2023 annual average. Florida, California, New York, and Texas were the primary hotspots, with ten counties in Florida confirming local transmissions. The U.S. Department of Health and Human Services, through its 2024 National Public Health Strategy, has spotlighted vector-borne diseases as a federal priority. This strategy promotes collaboration between the CDC and EPA, leading to widespread consumer education without the need for individual brand marketing. As the disease threat grows, there's a heightened institutional interest in spatial repellent technology, moving beyond traditional skin-applied formats. SC Johnson's Guardian, in August 2025, became the first spatial repellent to earn a WHO policy nod, hinting at a potential shift of this product category from public health channels to mainstream retail in North America. Moreover, school prevention campaigns and government travel advisories serve as free educational tools, broadening the market for insect repellents without added marketing costs.

Outdoor recreation and travel-led usage peaks

In 2024, outdoor recreation in North America generated a whopping USD 1.2 trillion in economic output, accounting for 2.3% of the GDP and supporting 5 million jobs, as reported by the US Bureau of Economic Analysis. This scale underscores the mainstream economic significance of outdoor recreation, moving it beyond its previously perceived niche status. According to the OIA's 2025 Participation Trends Report, the US outdoor participant base grew by 3% year-on-year, reaching 181.1 million Americans in 2024. Notably, hiking and camping each welcomed over 2 million new participants, serving as gateway activities that heighten exposure to mosquitoes and subsequently drive repellent purchases. KOA's 2026 Camping and Outdoor Hospitality Report highlighted that over 52 million North American households went camping in 2025. Outdoor hospitality spending surged to USD 66 billion, marking a USD 5 billion jump from 2024. This data confirms that the post-pandemic enthusiasm for outdoor activities hasn't waned to pre-2020 levels. Reflecting this family-oriented outdoor trend, the Kids end-user segment is projected to grow at a 7.12% CAGR through 2031. As families increasingly incorporate camping, hiking, and waterside recreation into their travel plans, the frequency and diversity of pediatric-specific repellent use occasions are expanding.

Safety perception risks around synthetic actives

Despite decades of endorsement from the EPA and Health Canada, DEET's safety narrative is losing ground, especially among parents of young children. These parents, who frequently apply repellents on their children's sensitive skin, are increasingly swayed by perception over evidence. A 2025 study in PubMed Central highlighted potential risks: it found epidemiological links between DEET exposure and negative impacts on sex hormones and bone mass in children and adolescents. If these findings gain traction on a larger scale, they could prompt a push for pediatric reformulations and heighten safety concerns beyond the current evidence. Meanwhile, Health Canada, in its proposed re-evaluation decision PRVD2025-09 (October 2025), is advocating for updated DEET product labels. These include concentration guidelines for children, underscoring the scrutiny reshaping parental choices in repellent formulations. While conventional repellents held an 82.72% share of the ingredient segment in 2025, brand equity is being chipped away by perception risks. Premium retailers are increasingly favoring "clean" alternatives on their shelves, and online parenting communities are amplifying safety concerns, reaching audiences far beyond the study's epidemiological significance. Yet, there's a self-imposed limit: DEET's established effectiveness against Aedes aegypti and Culex pipiens in high-risk areas outshines most natural alternatives. However, this perception gap is poised to stifle growth rates in the conventional segment for the foreseeable future.

Other drivers and restraints analyzed in the detailed report include:

• Retail premiumization toward natural and DEET-free formats
• E-commerce-enabled trial, subscription, and replenishment behavior
• Regulatory friction for novel actives and claims substantiation

Segment Analysis

In 2025, the Spray/Aerosol format held a 43.79% share of North America's mosquito repellent market, driven by consumer familiarity and multi-surface versatility. Active ingredients like DEET, picaridin, and IR3535, validated by EPA and Health Canada, further reinforce its dominance. The format excels in outdoor activities such as camping, hiking, and fishing, where ease of reapplication and high-concentration formulations for Aedes and Culex vectors strengthen its mass-market appeal. The Liquid Vaporizer is the fastest-growing product type, with a 6.96% CAGR through 2031, fueled by demand for contactless, odor-neutral protection in indoor and patio spaces. This shift from skin-applied formats creates distinct retail positioning and higher average selling prices. Coils remain relevant in outdoor and lower-income segments, particularly in Mexico, while Creams, Lotions, and Roll-ons gain traction as precision-application options for children and sensitive-skin users, offering reduced systemic absorption.

Thermacell's June 2026 launch of LIV 2.0, an EPA-registered system protecting up to 3,140 sq. ft. per hub against mosquitoes and no-see-ums, highlights the growing importance of technology-driven zone formats in premium outdoor and institutional markets. Patches and Wearables, though niche, are growing steadily, driven by demand for hands-free convenience among younger North Americans. Another trend to monitor is the rapid adoption of rechargeable zone devices in the US and Canada, which could accelerate the decline of coil demand. As smoke-free formats gain traction among urban-adjacent outdoor users, private-label coil suppliers may lag behind branded vaporizer players who are actively educating the market.

Natural mosquito repellents are projected to grow at a 6.81% CAGR through 2031. This growth is outpacing the conventional formulations, which until recently enjoyed a stable and largely uncontested position. In 2025, conventional mosquito repellents commanded 82.72% of the ingredient-type segment. This dominance underscores the enduring consumer trust in DEET, picaridin, and IR3535. These ingredients boast multi-decade efficacy validation in high-exposure vector environments and enjoy dual registration status under both EPA and Health Canada frameworks. The divergent growth trajectories of the two segments can be attributed to a generational shift in ingredient transparency expectations. Millennial parents, for instance, are now scrutinizing repellent products through the same clean-label lens they apply to food and personal care. This has led them to favor EPA-approved botanical actives, such as Oil of Lemon Eucalyptus, and picaridin, which serve as a middle ground between fully synthetic and entirely botanical formulations.

In the naturals segment, the key takeaway isn't its current size but its rapid ascent in shelf-space within mass-market retail. This trend often signals mainstream adoption, a precursor to volume surges in consumer goods. A 2025 PMC study hinted at a potential link between DEET exposure and endocrine disruption markers in children. Should larger cohort studies validate this, it might spur a regulatory-driven reformulation mandate, propelling the growth of natural repellents beyond current projections. Moreover, advancements like the microencapsulation of citronella and lemon eucalyptus oil are narrowing the protection-duration gap with synthetic DEET. This progress empowers natural brands to compete in a wider array of outdoor and disease-risk scenarios, effectively addressing a core performance concern that has historically constrained their market reach.

Complete Report Scope:

• Product Type
  • Liquid Vaporizer
  • Coils
  • Spray/Aerosol
  • Creams, Lotions, and Roll-ons
  • Patches and Wearables
  • Other Product Types
• Ingredient Type
  • Natural Mosquito Repellent
  • Conventional Mosquito Repellent
• End User
  • Adults
  • Kids
• Distribution Channel
  • Supermarkets/Hypermarkets
  • Convenience Stores
  • Pharmacies and Drug Stores
  • Online Retail Channels
  • Other Distribution Channels
• Geography
  • United States
  • Canada
  • Mexico
  • Rest of North America

List of Companies Covered in this Report:

• S. C. Johnson & Son, Inc.
• Reckitt Benckiser Group plc
• Spectrum Brands Holdings, Inc.
• 3M Company
• The Coleman Company, Inc.
• Thermacell Repellents, Inc.
• Quantum Health, Inc.
• Coghlan's Ltd.
• Tender Corporation
• Sawyer Products, Inc.
• The Avon Company
• Godrej Consumer Products Limited
• Dabur India Ltd.
• Jyothy Laboratories Ltd.
• Newell Brands Inc.
• Hello Bello LLC
• Murphy's Naturals, Inc.
• PIC Corporation
• Henkel AG and Co. KGaA
• The Honest Company, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support